by Eli Lilly
Eligible for BMI of 27* or 30 kg/m²*Check Eligibility
Mounjaro (tirzepatide) is an innovative injectable prescription medication for chronic weight management in adults. It combines the effects of GIP and GLP-1 hormones to regulate appetite and improve metabolic function.
As the first dual GIP and GLP-1 receptor agonist, Mounjaro offers superior weight loss results compared to single-action medications. It targets multiple pathways involved in weight regulation for comprehensive effects.
Clinical trials show Mounjaro can help patients lose up to 22% of their body weight when combined with lifestyle changes. The medication follows a structured dose escalation to optimize tolerability.
Mounjaro is approved for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions like type 2 diabetes.
Mounjaro treatment typically begins with a 4-week dose escalation period at 2.5mg before increasing in 2.5mg increments every 4 weeks until reaching the target maintenance dose (ranging from 5mg to 15mg weekly based on individual response). This gradual titration helps minimize gastrointestinal side effects.
Mounjaro is a prescription-only medication. You'll need to complete a consultation with one of our healthcare professionals to determine if it's suitable for you.